Clinical uptake of EEG AI hinges on explainability as much as accuracy; current XAI techniques are frequently fragile, inconsistent, and poorly aligned with neurophysiology, creating regulatory and adoption headwinds for commercialization.

Explainable Artificial Intelligence (XAI) for EEG Analysis: A Survey on Recent Trends and Advancements

Vassilis Lyberatos, Georgios Kontos, Nikolaos Spanos, Orfeas Menis Mastromichalakis, Athanasios Voulodimos, GIORGOS STAMOU · March 05, 2026 · AI

openalex review_meta n/a evidence 7/10 relevance DOI Source PDF

Explainability is central to clinical EEG AI adoption, but current XAI methods for EEG are often unstable, inconsistent across inputs and preprocessing steps, and insufficiently validated against neuroscientific knowledge or clinical utility.

Recent advancements in XAI have radically changed the way that AI systems are evaluated, as transparency and trustworthiness are now valued as highly as performance. This is especially true in medical applications, as, in order for such tools to be used in practical applications, interpretability is a key requirement for clinical adoption. Electroencephalography (EEG) analysis, in particular, has seen a significant rise in research, as the difficult and complex nature of EEG signals benefits from these methods, enabling researchers and practitioners to gain new insights from the vast amount of data that is now available. This survey presents a comprehensive analysis of the latest trends and advancements in XAI for EEG analysis. First, we provide a brief overview of fundamental EEG tasks, available datasets, and AI model approaches used for analysis. Then, we classify XAI methods using well-established taxonomies in XAI research, such as locality and generalization of explanations. By exploring all relevant XAI techniques in EEG analysis, our study offers researchers a clear perspective on the current state of the field and identifies potential research gaps. Our review indicates that current XAI approaches for EEG often face limitations in robustness, consistency, and neuroscientific grounding. These findings highlight the need for more reliable and domain-informed explainability methods to support trustworthy EEG analysis in research and clinical practice.

Summary

Main Finding

XAI techniques have become central to EEG analysis because interpretability is necessary for clinical adoption; however, current explainability methods for EEG frequently lack robustness, consistency, and alignment with neuroscientific knowledge, limiting their trustworthiness and practical utility.

Key Points

Motivation: Clinical and research EEG applications require explanations as much as raw predictive performance to enable clinician trust, regulatory acceptance, and safe deployment.
Tasks covered: seizure detection, sleep staging, brain–computer interfaces (BCI), cognitive/emotional state recognition, and diagnostic/supportive tools.
Models used: deep learning (CNNs, RNNs, attention/transformers), classical ML, and hybrid pipelines (feature extraction + classifier).
XAI methods applied to EEG: gradient-based saliency, Integrated Gradients, LRP, CAM/Grad-CAM, occlusion/perturbation, model-agnostic methods (LIME, SHAP), concept-based methods (TCAV), and counterfactual explanations.
Taxonomy emphasized: local vs global explanations; model-specific vs model-agnostic; post-hoc vs intrinsic interpretability.
Evaluation gaps: most studies focus on qualitative visualizations (heatmaps) rather than quantitative, reproducible metrics; few evaluate neuroscientific validity or clinical usefulness; robustness to noise and preprocessing is often untested.
Identified limitations: sensitivity to hyperparameters and preprocessing, inconsistent explanations across similar inputs, poor correlation with known neurophysiology, and scarcity of human/clinical validation studies.
Research gaps: standardized evaluation metrics, robustness/consistency-focused XAI methods, domain-informed explanation frameworks, longitudinal/clinical impact studies.

Data & Methods

Typical datasets referenced in the literature: public EEG collections used across tasks (examples commonly used in the field include TUH EEG Corpus, BCI Competition datasets, PhysioNet sleep databases, CHB-MIT for pediatric seizures), plus many small/clinical cohorts.
Preprocessing pipelines: filtering, artifact removal (ICA), re-referencing, segmentation—choices materially affect XAI outputs.
Modeling approaches: end-to-end deep models (1D/2D convolutions on raw or time–frequency representations), recurrent architectures for temporal dynamics, attention mechanisms, and hybrid feature-based classifiers.
XAI techniques applied:
- Gradient-based attributions (saliency maps, Integrated Gradients)
- Layer-wise relevance propagation (LRP)
- Class activation mapping (CAM, Grad-CAM)
- Perturbation/occlusion analyses
- Model-agnostic surrogates (LIME), Shapley-based (SHAP)
- Concept-level explanations (TCAV) and counterfactuals
Evaluation methods reported:
- Visual inspection by researchers or clinicians
- Correlation with known biomarkers/frequency bands
- Ablation/perturbation faithfulness tests
- Few studies report standardized quantitative metrics for robustness, stability, or neuroscientific fidelity

Implications for AI Economics

Value proposition and adoption: Explainability materially affects the economic value of EEG AI tools—models that are transparent and clinically credible are more likely to be adopted, reimbursed, and integrated into care pathways, increasing market size.
Investment priorities: Funding and commercial interest should prioritize robustness, clinical validation, and domain-aligned XAI development, not only accuracy benchmarks. Investors and firms will favour solutions that demonstrate consistent, validated explanations.
Regulation and liability: Weak or inconsistent explanations increase regulatory and medico-legal risk. Standardized, validated XAI can lower compliance costs and liability exposure, affecting pricing, insurance, and procurement decisions.
Market segmentation: Demand will bifurcate—high-value clinical markets require rigorous explainability and neuroscientific grounding (higher willingness-to-pay), while research/consumer segments may tolerate black-box models (lower margins).
Cost–benefit and deployment: Developing robust, clinically validated XAI increases upfront R&D costs but can accelerate adoption, reduce downstream monitoring costs, and enable higher reimbursement; formal economic assessments (cost-effectiveness, value-of-information) should include explainability as an input.
Labor and workflows: Explainable EEG tools can shift clinician workflows by enabling faster decision-making and reducing requirement for specialized interpretation, with implications for training, staffing, and productivity metrics.
Standards and market coordination: The field needs standard evaluation metrics and benchmarks for XAI in EEG; such standards will reduce information asymmetry, lower transaction costs, and facilitate market growth (comparable to performance benchmarks).
Risk to market growth: Without improvements in robustness, consistency, and neuroscientific validity, clinical uptake will be constrained, slowing commercialization and reducing anticipated returns for developers focused only on performance.

Summary takeaway: For EEG AI to realize commercial and clinical value, economic strategies must allocate resources to rigorous, domain-informed explainability work—this reduces regulatory and adoption friction, underpins pricing and reimbursement, and ultimately determines the size and speed of the market.

Assessment

Paper Typereview_meta Evidence Strengthn/a — This is a literature synthesis rather than an empirical study producing causal estimates; it summarizes methods, datasets, and gaps across published work rather than generating new causal evidence. Methods Rigormedium — Covers a wide range of tasks, models, XAI techniques and datasets and clearly identifies evaluation gaps (robustness, neuroscientific validity, clinical validation), but lacks a transparent, reproducible search strategy and quantitative synthesis typical of high-rigor systematic reviews. SampleNarrative review of EEG XAI literature drawing on public EEG datasets commonly used across tasks (e.g., TUH EEG Corpus, BCI Competition datasets, PhysioNet sleep databases, CHB-MIT) plus smaller clinical cohorts; studies reviewed span tasks (seizure detection, sleep staging, BCI, cognitive/emotional state recognition) and modeling approaches (end-to-end deep models, hybrid feature-based pipelines) with preprocessing steps like filtering, ICA, re-referencing and segmentation frequently reported. Themesadoption governance human_ai_collab productivity GeneralizabilityHeterogeneous tasks and datasets (seizure detection, sleep staging, BCI, diagnostics) limit cross-task generalization., Many source studies use small clinical cohorts or public benchmarks that may not represent real-world clinical populations or device variability., Preprocessing and model choices materially change XAI outputs, so findings about XAI reliability may not generalize across pipelines., Conclusions rely largely on qualitative visual assessments; lack of standardized quantitative metrics reduces reproducibility across settings., Economic implications are inferential and context-dependent (healthcare system, regulation, reimbursement), so market predictions are not directly transferable across regions or specialties.

Claims (23)

Claim	Direction	Confidence	Outcome	Details
XAI techniques have become central to EEG analysis because interpretability is necessary for clinical adoption. Adoption Rate	positive	medium	importance/centrality of XAI for clinical adoption	0.02
Current explainability methods for EEG frequently lack robustness, consistency, and alignment with neuroscientific knowledge, limiting their trustworthiness and practical utility. Ai Safety And Ethics	negative	medium	robustness/consistency/neuroscientific validity of explanations (trustworthiness)	0.02
Clinical and research EEG applications require explanations as much as raw predictive performance to enable clinician trust, regulatory acceptance, and safe deployment. Ai Safety And Ethics	positive	medium	clinician trust, regulatory acceptance, safety of deployment	0.02
The literature on EEG XAI covers tasks including seizure detection, sleep staging, brain–computer interfaces (BCI), cognitive/emotional state recognition, and diagnostic/supportive tools. Other	null_result	high	task domains addressed by EEG XAI studies	0.04
Models used in EEG XAI work include deep learning architectures (CNNs, RNNs, attention/transformers), classical machine learning, and hybrid pipelines combining feature extraction with classifiers. Other	null_result	high	model architectures applied to EEG tasks	0.04
XAI methods applied to EEG in the literature include gradient-based saliency methods, Integrated Gradients, layer-wise relevance propagation (LRP), CAM/Grad-CAM, occlusion/perturbation analyses, LIME, SHAP, TCAV, and counterfactual explanations. Other	null_result	high	types of XAI techniques used	0.04
A common taxonomy emphasized in EEG XAI work distinguishes local vs global explanations, model-specific vs model-agnostic methods, and post-hoc vs intrinsically interpretable models. Other	null_result	high	taxonomic classification of explanation types	0.04
Most studies focus on qualitative visualizations (e.g., heatmaps) rather than quantitative, reproducible metrics for explanation quality; few evaluate neuroscientific validity or clinical usefulness, and robustness to noise and preprocessing is often untested. Research Productivity	negative	medium	evaluation rigor: qualitative vs quantitative; assessment of robustness and clinical/neuroscientific validity	0.02
Identified methodological limitations include sensitivity of explanations to hyperparameters and preprocessing choices, inconsistent explanations across similar inputs, and poor correlation with known neurophysiology. Ai Safety And Ethics	negative	medium	stability/consistency of explanations and alignment with neurophysiological knowledge	0.02
There is a scarcity of human/clinical validation studies testing whether explanations improve clinician decision-making or align with clinical reasoning. Research Productivity	negative	medium	presence/absence of human/clinical validation	0.02
Research gaps include the need for standardized evaluation metrics, robustness- and consistency-focused XAI methods, domain-informed explanation frameworks, and longitudinal/clinical impact studies. Research Productivity	null_result	medium	recommended research directions / missing evaluation components	0.02
Typical datasets used in EEG XAI research include public collections such as the TUH EEG Corpus, BCI Competition datasets, PhysioNet sleep databases, CHB-MIT for pediatric seizures, as well as many small/clinical cohorts. Other	null_result	high	datasets employed in EEG XAI studies	0.04
Preprocessing pipelines (filtering, artifact removal such as ICA, re-referencing, segmentation) materially affect XAI outputs. Ai Safety And Ethics	negative	medium	sensitivity of explanation outputs to preprocessing steps	0.02
Modeling approaches in the literature include end-to-end deep models operating on raw or time–frequency representations, recurrent architectures for temporal dynamics, attention mechanisms, and hybrid feature-based classifiers. Other	null_result	high	specific modeling strategies applied to EEG	0.04
Evaluation methods reported commonly include visual inspection by researchers/clinicians, correlation with known biomarkers/frequency bands, and ablation/perturbation faithfulness tests; few studies report standardized quantitative metrics for robustness, stability, or neuroscientific fidelity. Research Productivity	null_result	high	types of evaluation methods used to assess explanations	0.04
Explainability materially affects the economic value and adoption of EEG AI tools: transparent and clinically credible models are more likely to be adopted, reimbursed, and integrated into care pathways, increasing market size. Adoption Rate	positive	medium	economic adoption/reimbursement/market size	0.02
Funding and commercial interest should prioritize robustness, clinical validation, and domain-aligned XAI development rather than focusing solely on accuracy benchmarks. Research Productivity	positive	medium	recommended investment priorities for R&D and commercialization	0.02
Weak or inconsistent explanations increase regulatory and medico-legal risk; standardized, validated XAI can lower compliance costs and liability exposure. Regulatory Compliance	negative	medium	regulatory/compliance and legal risk	0.02
Market demand is likely to bifurcate: high-value clinical markets will require rigorous explainability and neuroscientific grounding (higher willingness-to-pay), while research and consumer segments may tolerate black-box models (lower margins). Market Structure	mixed	speculative	market segmentation / willingness-to-pay across segments	0.0
Developing robust, clinically validated XAI increases upfront R&D costs but can accelerate adoption, reduce downstream monitoring costs, and enable higher reimbursement. Firm Productivity	positive	medium	R&D costs, adoption rate, downstream costs, reimbursement potential	0.02
Explainable EEG tools can shift clinician workflows by enabling faster decision-making and reducing the requirement for specialized interpretation, with implications for training, staffing, and productivity. Organizational Efficiency	positive	speculative	clinician workflow efficiency, training/staffing needs, productivity	0.0
The field needs standard evaluation metrics and benchmarks for XAI in EEG; such standards will reduce information asymmetry, lower transaction costs, and facilitate market growth. Adoption Rate	positive	medium	existence of standards/benchmarks and their effect on market dynamics	0.02
Without improvements in robustness, consistency, and neuroscientific validity of explanations, clinical uptake will be constrained, slowing commercialization and reducing returns for developers focused only on performance. Adoption Rate	negative	medium	clinical uptake, commercialization pace, developer returns	0.02